Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

MYNZ


Fundamental

Company: Mainz Biomed N.V
Sector: Healthcare
Industry: Diagnostics & Research
Country: Germany
Exchange: NASD
Index: -
P/E: -
EPS (ttm): -
Insider Own: 8.11%
Shs Outstand: 9.06M
Perf Week: -15.38%
Market Cap: 7.24M
Forward P/E: -
EPS next Y: -
Insider Trans: -
Shs Float: 8.33M
Perf Month: -28.57%
Enterprise Value: 8.42M
PEG: -
EPS next Q: -
Inst Own: 7.64%
Short Float: 3.87%
Perf Quarter: -41.18%
Income: -
P/S: -
EPS this Y: -
Inst Trans: -6.87%
Short Ratio: 0.57
Perf Half Y: -52.66%
Sales: -
P/B: 2.50
EPS next Y Percentage: -
ROA: -
Short Interest: 0.32M
Perf YTD: -28.57%
Book/sh: 0.32
P/C: 3.79
EPS next 5Y: -
ROE: -
52W High: 7.80 -89.74%
Perf Year: -87.75%
Cash/sh: 0.21
P/FCF: -
EPS past 3/5Y: 29.88% -52.02%
ROIC: -
52W Low: 0.60 33.33%
Perf 3Y: -99.70%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: 15.69% 16.01%
Gross Margin: -
Volatility W: 23.30%
Volatility M: 13.84%
Perf 5Y: -
Dividend TTM: -
EV/Sales: -
EPS Y/Y TTM: 11.95%
Oper. Margin: -
ATR (14): 0.13
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 0.43
Sales Y/Y TTM: -
Profit Margin: -
RSI (14): 32.42
Recom: 1.00
Dividend Gr. 3/5Y: - -
Current Ratio: 0.52
EPS Q/Q: -1121.45%
SMA20: -25.15%
Beta: 0.34
Target Price: 14.00
Payout: -
Debt/Eq: 1.23
Sales Q/Q: -
SMA50: -28.45%
Rel Volume: 0.10
Prev Close: 0.75
Employees: 26
LT Debt/Eq: 0.44
Earnings: Sep 03
SMA200: -48.88%
Avg Volume: 569.93K
Price: 0.80
IPO: Nov 05, 2021
Option/Short: No / Yes
EPS/Sales Surpr.: - -58.95%
Trades:
Volume: 54,172
Change: 6.52%

Technical:


Latest News:

mRNA Is Promising A Breakthrough In Fighting Cancer - Pfizer (NYSE:PFE) - Benzinga somewhat bullish
PFE MRNA MYNZ

Summary: Mainz Biomed is utilizing mRNA to revolutionize colorectal cancer diagnostics and prevention by developing a next-generation CRC screening tool with promising sensitivity and specificity results. Moderna is partnering with OpenAI to advance the future of mRNA medicine, showcasing the potential of mRNA in healthcare innovation.

Full article
2024-04-29T14:06:54Z